Articles19 August 2003
A Randomized, Placebo-Controlled Clinical Trial
    Author, Article, and Disclosure Information

    Cannabinoid use could potentially alter HIV RNA levels by two mechanisms: immune modulation or cannabinoidprotease inhibitor interactions (because both share cytochrome P-450 metabolic pathways).


    To determine the short-term effects of smoked marijuana on the viral load in HIV-infected patients.


    Randomized, placebo-controlled, 21-day intervention trial.


    The inpatient General Clinical Research Center at the San Francisco General Hospital, San Francisco, California.


    67 patients with HIV-1 infection.


    Participants were randomly assigned to a 3.95%-tetrahydrocannabinol marijuana cigarette, a 2.5-mg dronabinol (delta-9-tetrahydrocannabinol) capsule, or a placebo capsule three times daily before meals.


    HIV RNA levels, CD4+ and CD8+ cell subsets, and pharmacokinetic analyses of the protease inhibitors.


    62 study participants were eligible for the primary end point (marijuana group, 20 patients; dronabinol group, 22 patients; and placebo group, 20 patients). Baseline HIV RNA level was less than 50 copies/mL for 36 participants (58%), and the median CD4+ cell count was 340 × 109 cells/L. When adjusted for baseline variables, the estimated average effect versus placebo on change in log10 viral load from baseline to day 21 was 0.07 (95% CI, 0.30 to 0.13) for marijuana and 0.04 (CI, 0.20 to 0.14) for dronabinol. The adjusted average changes in viral load in marijuana and dronabinol relative to placebo were 15% (CI, 50% to 34%) and 8% (CI, 37% to 37%), respectively. Neither CD4+ nor CD8+ cell counts appeared to be adversely affected by the cannabinoids.


    Smoked and oral cannabinoids did not seem to be unsafe in people with HIV infection with respect to HIV RNA levels, CD4+ and CD8+ cell counts, or protease inhibitor levels over a 21-day treatment.


    • 1. Abel ELMarijuana: The First Twelve Thousand Years. New York: Plenum Pr; 1980. Google Scholar
    • 2. Sallan SEZinberg NEFrei EAntiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med1975;293:795-7. [PMID: 1099449] CrossrefMedlineGoogle Scholar
    • 3. Chang AEShiling DJStillman RCGoldberg NHSeipp CABarofsky I Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med1979;91:819-24. [PMID: 293141] LinkGoogle Scholar
    • 4. Frytak SMoertel CGO'Fallon JRRubin JCreagan ETO'Connell MJ Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann Intern Med1979;91:825-30. [PMID: 517882] LinkGoogle Scholar
    • 5. Chang AEShiling DJStillman RCGoldberg NHSeipp CABarofsky I A prospective evaluation of delta-9-tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer1981;47:1746-51. [PMID: 6261926] CrossrefMedlineGoogle Scholar
    • 6. Gorter RSeefried MVolberding PDronabinol effects on weight in patients with HIV infection [Letter]. AIDS1992;6:127. [PMID: 1311935] CrossrefMedlineGoogle Scholar
    • 7. Beal JEOlson RLaubenstein LMorales JOBellman PYangco B Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage1995;10:89-97. [PMID: 7730690] CrossrefMedlineGoogle Scholar
    • 8. Kotler DPTierney ARWang JPierson RNMagnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr1989;50:444-7. [PMID: 2773823] CrossrefMedlineGoogle Scholar
    • 9. Agurell SHalldin MLindgren JEOhlsson AWidman MGillespie H Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev1986;38:21-43. [PMID: 3012605] MedlineGoogle Scholar
    • 10. Abrams DIChild CCMitchell TMarijuana, the AIDS wasting syndrome, and the U.S. government [Letter]. N Engl J Med1995;333:670-1. CrossrefGoogle Scholar
    • 11. Abrams DIMedical marijuana: tribulations and trials. J Psychoactive Drugs1998;30:163-9. [PMID: 9692378] CrossrefMedlineGoogle Scholar
    • 12. Abrams DIPotential interventions for HIV/AIDS wasting: an overview. J Acquir Immune Defic Syndr2000;25 Suppl 1 S74-80. [PMID: 11126431] CrossrefMedlineGoogle Scholar
    • 13. Palella FJDelaney KMMoorman ACLoveless MOFuhrer JSatten GA Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med1998;338:853-60. [PMID: 9516219] CrossrefMedlineGoogle Scholar
    • 14. Mocroft AVella SBenfield TLChiesi AMiller VGargalianos P Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet1998;352:1725-30. [PMID: 9848347] CrossrefMedlineGoogle Scholar
    • 15. Ledergerber BEgger MErard VWeber RHirschel BFurrer H AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. JAMA1999;282:2220-6. [PMID: 10605973] CrossrefMedlineGoogle Scholar
    • 16. Acosta EPKakuda TNBrundage RCAnderson PLFletcher CVPharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis2000;30 Suppl 2 S151-9. [PMID: 10860900] CrossrefMedlineGoogle Scholar
    • 17. Piscitelli SCGallicano KDInteractions among drugs for HIV and opportunistic infections. N Engl J Med2001;344:984-96. [PMID: 11274626] CrossrefMedlineGoogle Scholar
    • 18. Child CC, Mitchell TF, Abrams DI. Patterns of therapeutic marijuana use in two community-based cannabis buyers' cooperatives [Abstract]. 12th World AIDS Conference, Geneva, 28 June3 July 1998. Abstract no. 60569:1105. Google Scholar
    • 19. Braitstein P, Kendall TR, Chan K, Montaner JSG, O'Shaughnessy MV, Hogg RS. Mary-Jane and her patients: sociodemographic and clinical characteristics of HIV+ individuals using medicinal marijuana and antiretrovirals in British Columbia, Canada [Abstract]. XIIIth International AIDS Conference, Durban, South Africa, 914 July 2000. Page 326, abstract no. ThPeB5055. Google Scholar
    • 20. Yamamoto IWatanabe KNarimatsu SYoshimura HRecent advances in the metabolism of cannabinoids. Int J Biochem Cell Biol1995;27:741-6. [PMID: 7584607] CrossrefMedlineGoogle Scholar
    • 21. Watanabe KMatsunaga TYamamoto IFunae YYoshimura HInvolvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol Pharm Bull1995;18:1138-41. [PMID: 8535411] CrossrefMedlineGoogle Scholar
    • 22. Benowitz NLJones RTEffects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Antipyrine, pentobarbital, and ethanol. Clin Pharmacol Ther1977;22:259-68. [PMID: 891094] CrossrefMedlineGoogle Scholar
    • 23. Benowitz NLNguyen TLJones RTHerning RIBachman JMetabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther1980;28:115-20. [PMID: 7389248] CrossrefMedlineGoogle Scholar
    • 24. Pertwee RGPharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther1997;74:129-80. [PMID: 9336020] CrossrefMedlineGoogle Scholar
    • 25. Felder CCGlass MCannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol1998;38:179-200. [PMID: 9597153] CrossrefMedlineGoogle Scholar
    • 26. Nahas GGSuciu-Foca NArmand JPMorishima AInhibition of cellular mediated immunity in marihuana smokers. Science1974;183:419-20. [PMID: 4271816] CrossrefMedlineGoogle Scholar
    • 27. Friedman HKlein TWNewton CDaaka YMarijuana, receptors and immunomodulation. Adv Exp Med Biol1995;373:103-13. [PMID: 7668140] CrossrefMedlineGoogle Scholar
    • 28. Hollister LEMarijuana and immunity. J Psychoactive Drugs1992;24:159-64. [PMID: 1506999] CrossrefMedlineGoogle Scholar
    • 29. Wallace JMTashkin DPOishi JSBarbers RGPeripheral blood lymphocyte subpopulations and mitogen responsiveness in tobacco and marijuana smokers. J Psychoactive Drugs1988;20:9-14. [PMID: 3392635] CrossrefMedlineGoogle Scholar
    • 30. U.S. Public Health Service. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Accessed at on 17 February 2003. Google Scholar
    • 31. Yeni PGHammer SMCarpenter CCCooper DAFischl MAGatell JM Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA2002;288:222-35. [PMID: 12095387] CrossrefMedlineGoogle Scholar
    • 32. Dybul MFauci ASBartlett JGKaplan JEPau AKGuidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med2002;137:381-433. [PMID: 12617573] LinkGoogle Scholar
    • 33. Johnson M, Petersen A, Winslade J, Clendennin N. Comparison of BID and TID dosing of VIRACEPT (nelfinavir, NFV) in combination with stavudine (d4T) and lamivudine (3TC) [Abstract]. Proceedings of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 15 February 1998. Page 148, abstract no. 373. Google Scholar
    • 34. Foltin RWFischman MWByrne MFEffects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite1988;11:1-14. [PMID: 3228283] CrossrefMedlineGoogle Scholar
    • 35. Kosel BWAweeka FTBenowitz NLShade SBHilton JFLizak PS The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS2002;16:543-50. [PMID: 11872997] CrossrefMedlineGoogle Scholar
    • 36. Hughes MDJohnson VAHirsch MSBremer JWElbeik TErice A Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med1997;126:929-38. [PMID: 9182469] LinkGoogle Scholar
    • 37. Paxton WBCoombs RWMcElrath MJKeefer MCHughes JSinangil F Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis1997;175:247-54. [PMID: 9203644] MedlineGoogle Scholar
    • 38. Efron BTibshirani RJAn Introduction to the Bootstrap. London: Chapman and Hall; 1993:178-88, 214-8, 398-403. Google Scholar
    • 39. Lesaffre EVerbeke GLocal influence in linear mixed models. Biometrics1998;54:570-82. [PMID: 9629645] CrossrefMedlineGoogle Scholar
    • 40. Bredt BMHiguera-Alhino DShade SBHebert SJMcCune JMAbrams DIShort-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. J Clin Pharmacol2002;42:82S-89S. [PMID: 12412840] CrossrefMedlineGoogle Scholar
    • 41. Kane BMedical marijuana: the continuing story. Ann Intern Med2001;134:1159-62. [PMID: 11412075] LinkGoogle Scholar
    • 42. Mulligan K, Abrams DI, Leiser RJ, Schambelan M. Body composition changes in HIV-infected men consuming self-selected diets during a placebo-controlled inpatient study of cannabinoids [Abstract]. Proceedings of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 48 February 2001. Page 238, abstract no. 647. Google Scholar
    • 43. Joy JE, Watson SJ, Benson JA, eds. Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Pr; 1999. Google Scholar
    • 44. University of California Center for Medicinal Cannabis Research. Accessed at on 17 February 2003. Google Scholar